(VIANEWS) – ESSILORLUXOTTICA (EL.PA) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| ESSILORLUXOTTICA (EL.PA) | €209.70 | 1.89% | 6.3% |
| TUBIZE-FIN (TUB.BR) | €98.10 | 1% | 4.97% |
| VIRBAC (VIRP.PA) | €346.00 | 0.37% | 13.84% |
| SARTORIUS STED BIO (DIM.PA) | €264.30 | 0.35% | 8.15% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. ESSILORLUXOTTICA (EL.PA)
1.89% Forward Dividend Yield and 6.3% Return On Equity
EssilorLuxottica Société anonyme designs, manufactures, and distributes ophthalmic lenses, frames, and sunglasses in Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and North America. It operates through Professional Solutions and Direct to Consumer segments. The company offers lens under the Essilor, Varilux, Crizal, Eyezen, Stellest, Xperio, Transitions, Ray-Ban, Oakley, Barberini, KODAK Lens, Nikon, Shamir, eyexpert, iWear, Humanware, and Optifog brands. It also provides finishing equipment, vision performance screening, eye examination and refractions, fitting parameter measurements, and small tools and consumables under the Essilor Instruments brand; high-tech equipment for optical surfacing, polishing, measuring, coating, and finishing, as well as consumables, tools, and services under the Satisloh brand. In addition, the company provides eyewear products under the Ray-Ban, Oakley, Persol, Oliver Peoples, Vogue Eyewear, Arnette, Alain Mikli, Costa, Bliz, Native, Luxottica, Sferoflex, Bolon, Molsion, DbyD, and Unofficial and Seen, as well as other Licensed brands. In addition, the company designs, develops, markets, and maintains lens edging and mounting instruments for opticians and prescription laboratories; and optometry instruments for eyecare professionals, schools, occupational medicine centers, military, and other institutions. It wholesales its products to independent opticians, distributors, third-party e-commerce platforms, and large retail chains in the eyecare and eyewear industry; and sells directly to consumers through the network of brick and mortar retail network and its online channels. The company was formerly known as Essilor International Société Anonyme and changed its name to EssilorLuxottica Société anonyme in October 2018. EssilorLuxottica Société anonyme was founded in 1849 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, ESSILORLUXOTTICA has a trailing twelve months EPS of €5.08.
PE Ratio
ESSILORLUXOTTICA has a trailing twelve months price to earnings ratio of 41.28. Meaning, the purchaser of the share is investing €41.28 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.3%.
Yearly Top and Bottom Value
ESSILORLUXOTTICA’s stock is valued at €209.70 at 07:30 EST, higher than its 52-week high of €209.60.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ESSILORLUXOTTICA’s stock is considered to be overbought (>=80).
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on May 6, 2024, the estimated forward annual dividend rate is 3.95 and the estimated forward annual dividend yield is 1.89%.
More news about ESSILORLUXOTTICA.
2. TUBIZE-FIN (TUB.BR)
1% Forward Dividend Yield and 4.97% Return On Equity
Financière de Tubize SA operates as a mono holding company whose sole investment is a stake in UCB which is a biopharma company in Belgium. The company was incorporated in 1928 and is based in Brussels, Belgium.
Earnings Per Share
As for profitability, TUBIZE-FIN has a trailing twelve months EPS of €1.98.
PE Ratio
TUBIZE-FIN has a trailing twelve months price to earnings ratio of 49.55. Meaning, the purchaser of the share is investing €49.55 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.97%.
Yearly Top and Bottom Value
TUBIZE-FIN’s stock is valued at €98.10 at 07:30 EST, above its 52-week high of €97.40.
Volume
Today’s last reported volume for TUBIZE-FIN is 6935 which is 69.37% below its average volume of 22645.
Volatility
TUBIZE-FIN’s last week, last month’s, and last quarter’s current intraday variation average was 0.50%, 0.30%, and 1.34%.
TUBIZE-FIN’s highest amplitude of average volatility was 0.80% (last week), 1.09% (last month), and 1.34% (last quarter).
Moving Average
TUBIZE-FIN’s worth is higher than its 50-day moving average of €91.80 and way higher than its 200-day moving average of €76.32.
More news about TUBIZE-FIN.
3. VIRBAC (VIRP.PA)
0.37% Forward Dividend Yield and 13.84% Return On Equity
Virbac SA manufactures and sells a range of products and services for companion animals and farm animals in France, Europe, Latin America, North America, Asia, Pacific, and Africa and the Middle East. The company offers a range of vaccines, dental hygiene, reproduction, dermatology, parasiticides, diagnostic, antibiotics, and aquaculture products; and veterinary medicines for anesthesia, geriatrics, behavior, and injectable micronutrients, as well as petfood and electronic identification. It serves veterinarians, farmers, and pet owners. Virbac SA was founded in 1968 and is headquartered in Carros, France.
Earnings Per Share
As for profitability, VIRBAC has a trailing twelve months EPS of €14.12.
PE Ratio
VIRBAC has a trailing twelve months price to earnings ratio of 24.5. Meaning, the purchaser of the share is investing €24.5 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.84%.
Moving Average
VIRBAC’s value is under its 50-day moving average of €351.41 and way above its 200-day moving average of €312.38.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Jun 25, 2024, the estimated forward annual dividend rate is 1.32 and the estimated forward annual dividend yield is 0.37%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 6.1%, now sitting on 1.25B for the twelve trailing months.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, VIRBAC’s stock is considered to be oversold (<=20).
More news about VIRBAC.
4. SARTORIUS STED BIO (DIM.PA)
0.35% Forward Dividend Yield and 8.15% Return On Equity
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.
Earnings Per Share
As for profitability, SARTORIUS STED BIO has a trailing twelve months EPS of €3.36.
PE Ratio
SARTORIUS STED BIO has a trailing twelve months price to earnings ratio of 78.66. Meaning, the purchaser of the share is investing €78.66 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 8.15%.
More news about SARTORIUS STED BIO.
